Laidlaw Capital Markets helps clients gain access to capital through the public markets. Our expertise includes specialized offerings such as:
Follow-on and secondary offerings
Confidentially marketed follow-ons
Registered directs, and PIPEs
Investment Banking Team
James P. AhernManaging Partner, Head of Capital Markets
James Ahern serves as Managing Partner and Head of Capital Markets at Laidlaw & Company (UK) Ltd. Jim joined the firm in October of 2010 and focuses on arranging financing for both private and public companies, mainly within the healthcare vertical. Over the past 5 years, Jim has strategically grown Laidlaw’s capital markets team and overseen the firms significant market share expansion in the capital markets. Prior to Laidlaw, Mr. Ahern served as Managing Director of the Private Client Group at Aegis Capital Corp., a private investment firm. Before Aegis Capital, Mr. Ahern was a Vice President at Casimir Capital, a boutique investment bank.
Outside of the firm, Mr. Ahern is an active supporter of his alma mater the Northfield Mount Hermon School amongst other charitable endeavors.
Matt DormerManaging Director - Healthcare Investment Banking
Matt Dormer joins Laidlaw & Co. (UK) Ltd. from Summer Street Research Partners. During his time at Summer Street he completed more than 40 transactions which raised over $1.5 billion for biotechnology, medical device, and healthcare IT companies. Matt formerly worked for Wellington Management Company in the portfolio advisor group and previously worked in the equity research group covering the biotechnology sector at Fulcrum Global Partners in New York City. Prior to his experience in equity research, Matt was a scientist for a start-up biotechnology company and a research associate and teaching fellow at Harvard University, where he conducted research on tumor suppressor genes. Matt graduated from Davidson College with a BS in biology and received an MBA in finance from Northeastern University
Initial Public Offerings
Given Laidlaw Capital Markets success raising capital for companies, we have expanded our Equity Capital Markets reach to the IPO market. Our expertise at identifying emerging healthcare companies uniquely separates us from other advisors. Our team of banking, capital markets, institutional sales and research professionals are committed to acting and executing as a unified team in order to deliver compelling results for issuers.
For existing public companies, Laidlaw Capital Markets research and distribution strength provides a valuable platform from which to lead or co-manage underwritten follow-on offerings and registered direct transactions. Our daily dialogue with healthcare focused investors provides us with a keen perspective on the capital markets and current investing climate. With a single sector focus, the Laidlaw & Company team helps corporate clients raise funds by accessing both domestic and international markets.
Confidentially Marketed Follow-Ons, Registered Directs, and PIPEs
Laidlaw Capital Markets has a proven track record executing confidentially marketed follow-ons, registered directs, and PIPEs. We also have experience in a wide variety of deal structures allowing us to provide our clients access to the capital markets. Through continuous innovation of our product and execution, Laidlaw Capital Markets delivers the highest quality outcome for its clients.
Laidlaw is committed to partnering with organizations in an advisory capacity. Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets. Our team is able to help organizations strategize and navigate goals on an individual company basis. Whether one is seeking transactions such as acquisitions, divestitures, and mergers, or “going private” transactions and management-led buyouts, we have the resources, experience, and capabilities to work closely with clients to achieve the desired results.